Gain Therapeutics (NASDAQ:GANX) Posts Earnings Results, Beats Estimates By $0.03 EPS

Gain Therapeutics (NASDAQ:GANX) announced its quarterly earnings data on Tuesday. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03, Zacks reports.

Gain Therapeutics Stock Up 2.9%

GANX stock opened at $2.12 on Thursday. The company has a market cap of $90.42 million, a price-to-earnings ratio of -4.24 and a beta of 0.19. Gain Therapeutics has a twelve month low of $1.48 and a twelve month high of $4.34. The business has a 50 day moving average price of $1.79 and a two-hundred day moving average price of $1.93. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.02.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. BTIG Research reissued a “buy” rating and set a $5.00 price objective on shares of Gain Therapeutics in a research note on Tuesday. Weiss Ratings cut shares of Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Wall Street Zen raised shares of Gain Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, June 21st. Roth Capital reaffirmed a “buy” rating on shares of Gain Therapeutics in a research report on Tuesday, May 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research report on Wednesday, July 1st. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.50.

Hedge Funds Weigh In On Gain Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in GANX. Sprott Inc. bought a new stake in Gain Therapeutics during the fourth quarter worth $39,000. Commonwealth Equity Services LLC bought a new position in shares of Gain Therapeutics in the 4th quarter valued at about $41,000. Millennium Management LLC acquired a new position in shares of Gain Therapeutics during the 4th quarter worth about $45,000. JPMorgan Chase & Co. acquired a new position in shares of Gain Therapeutics during the 3rd quarter worth about $47,000. Finally, Engineers Gate Manager LP bought a new stake in shares of Gain Therapeutics in the 4th quarter valued at about $47,000. 11.97% of the stock is owned by institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.